Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicinium in BCG-unresponsive CIS bladder cancer
NCT00462488Phase 2Completed
- Sponsor
- Sesen Bio
- Start
- Mar 2007
- Primary completion
- Oct 2009
- Modality
- scFv Fragments, Antibody-Drug Conjugates (ADCs), Immunotoxins
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of oportuzumab monatox in urothelial carcinoma in situ of the bladder (CIS) (2 arms), sponsored by Sesen Bio. Primary endpoint: 12-Week Efficacy / 13-Week Efficacy. Started Mar 2007; status: completed.
02
Drugs
oportuzumab monatox
03
Conditions
urothelial carcinoma in situ of the bladder (CIS)
Beyond the preview
Go deeper on NCT00462488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462488.